Glow-in-the-Dark dye could replace radioactive tracer in breast cancer surgery
NCT ID NCT07441733
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tests whether a fluorescent dye called indocyanine green (ICG) can effectively identify sentinel lymph nodes in breast cancer patients, potentially replacing the standard radioactive tracer. Forty women with early-stage breast cancer will receive both methods, and doctors will compare how often each finds the nodes. If ICG works as well, it could simplify the procedure and avoid radioactivity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Indocyanine Green (ICG)
What this could lead to
If successful, this could replace the standard radioactive tracer with a safer, more accessible dye for sentinel lymph node biopsy in breast cancer.
What could go wrong
This is a small pilot study (40 participants) at a single hospital, so results may not apply broadly. ICG may not identify nodes as reliably as the current method.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ospedale P. Pederzoli Casa di Cura Privata S.p.A.
RECRUITINGPeschiera del Garda, Verona, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••